Fabien Le Bras

1.8k total citations
41 papers, 519 citations indexed

About

Fabien Le Bras is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Fabien Le Bras has authored 41 papers receiving a total of 519 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 17 papers in Oncology and 9 papers in Pathology and Forensic Medicine. Recurrent topics in Fabien Le Bras's work include Amyloidosis: Diagnosis, Treatment, Outcomes (13 papers), Multiple Myeloma Research and Treatments (7 papers) and Peptidase Inhibition and Analysis (7 papers). Fabien Le Bras is often cited by papers focused on Amyloidosis: Diagnosis, Treatment, Outcomes (13 papers), Multiple Myeloma Research and Treatments (7 papers) and Peptidase Inhibition and Analysis (7 papers). Fabien Le Bras collaborates with scholars based in France, United States and Belgium. Fabien Le Bras's co-authors include Jehan Dupuis, Karim Belhadj, Corinne Haïoun, Valérie Molinier‐Frenkel, C. Marsault, Thibaud Damy, Bruno Royer, Bertrand Arnulf, Hervé Tilly and Sylvie Chevret and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Fabien Le Bras

40 papers receiving 506 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fabien Le Bras France 13 249 164 140 128 127 41 519
Zhengming Jin China 15 124 0.5× 270 1.6× 325 2.3× 72 0.6× 102 0.8× 98 660
Denise Pereira United States 12 128 0.5× 235 1.4× 175 1.3× 142 1.1× 103 0.8× 37 536
M. Yadira Hurley United States 15 138 0.6× 229 1.4× 93 0.7× 41 0.3× 144 1.1× 52 651
Clara Cesana Italy 15 214 0.9× 139 0.8× 439 3.1× 238 1.9× 96 0.8× 33 656
Amer Beitinjaneh United States 15 146 0.6× 337 2.1× 286 2.0× 70 0.5× 140 1.1× 64 696
Stephen J. Forman United States 19 222 0.9× 298 1.8× 456 3.3× 127 1.0× 185 1.5× 34 962
Meifeng Tu China 12 110 0.4× 471 2.9× 126 0.9× 90 0.7× 313 2.5× 65 747
Alexey Maschan Russia 17 147 0.6× 236 1.4× 477 3.4× 120 0.9× 80 0.6× 137 854
Hien Liu United States 11 156 0.6× 449 2.7× 144 1.0× 49 0.4× 153 1.2× 62 594
Keiki Kawakami Japan 11 106 0.4× 96 0.6× 297 2.1× 107 0.8× 105 0.8× 47 488

Countries citing papers authored by Fabien Le Bras

Since Specialization
Citations

This map shows the geographic impact of Fabien Le Bras's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fabien Le Bras with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fabien Le Bras more than expected).

Fields of papers citing papers by Fabien Le Bras

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fabien Le Bras. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fabien Le Bras. The network helps show where Fabien Le Bras may publish in the future.

Co-authorship network of co-authors of Fabien Le Bras

This figure shows the co-authorship network connecting the top 25 collaborators of Fabien Le Bras. A scholar is included among the top collaborators of Fabien Le Bras based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fabien Le Bras. Fabien Le Bras is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Matthys, Arthur, Fabien Le Bras, Alain Créange, et al.. (2024). Rate and characteristics of inflammatory neuropathies associated with brentuximab vedotin therapy. European Journal of Neurology. 31(7). e16285–e16285. 2 indexed citations
2.
Beldi‐Ferchiou, Asma, Vincent Audard, François Lemonnier, et al.. (2022). Evaluation of a new ELISA assay for monoclonal free‐light chain detection in patients with cardiac amyloidosis. SHILAP Revista de lepidopterología. 3(3). 828–837. 3 indexed citations
3.
Molinier‐Frenkel, Valérie, et al.. (2022). Revisiting the spectrum of IgM-related neuropathies in a large cohort of IgM monoclonal gammopathy. Journal of Neurology. 269(9). 4955–4960. 7 indexed citations
4.
Bézard, Mélanie, Mounira Kharoubi, Arnault Galat, et al.. (2022). Real-Life Evaluation of an Algorithm for the Diagnosis of Cardiac Amyloidosis. Mayo Clinic Proceedings. 98(1). 48–59. 3 indexed citations
5.
Oghina, Silvia, Wulfran Bougouin, Mounira Kharoubi, et al.. (2021). Echocardiographic Patterns of Left Ventricular Diastolic Function in Cardiac Amyloidosis: An Updated Evaluation. Journal of Clinical Medicine. 10(21). 4888–4888. 6 indexed citations
6.
Bézard, Mélanie, Silvia Oghina, Damien Vitiello, et al.. (2021). Dexamethasone is associated with early deaths in light chain amyloidosis patients with severe cardiac involvement. PLoS ONE. 16(9). e0257189–e0257189. 8 indexed citations
7.
Belhadj, Karim, Jehan Dupuis, Louise Roulin, et al.. (2021). Venetoclax induces profound and sustained responses in patients with relapsed/refractory light‐chain amyloidosis. British Journal of Haematology. 193(3). 674–677. 13 indexed citations
8.
Kharoubi, Mounira, Mélanie Bézard, Silvia Oghina, et al.. (2021). Assessing Cardiac Amyloidosis Subtypes by Unsupervised Phenotype Clustering Analysis. Journal of the American College of Cardiology. 78(22). 2177–2192. 9 indexed citations
9.
10.
Lévy, Michaël, Christiane Copie‐Bergman, Jehan Dupuis, et al.. (2020). Effectiveness and Safety of Subcutaneous Rituximab for Patients With Gastric MALT Lymphoma: A Case–Control Comparison With Intravenous Rituximab. Clinical Lymphoma Myeloma & Leukemia. 21(1). e32–e38. 5 indexed citations
11.
Abulizi, Mukedaisi, Mounira Kharoubi, Silvia Oghina, et al.. (2020). Extracardiac soft tissue uptake, evidenced on early 99mTc-HMDP SPECT/CT, helps typing cardiac amyloidosis and demonstrates high prognostic value. European Journal of Nuclear Medicine and Molecular Imaging. 47(10). 2396–2406. 17 indexed citations
12.
Dang, Julien, Mukedaisi Abulizi, Anissa Moktefi, et al.. (2019). Renal Infarction and Its Consequences for Renal Function in Patients With Cardiac Amyloidosis. Mayo Clinic Proceedings. 94(6). 961–975. 3 indexed citations
13.
Tannoury, Jenny, Aurélien Amiot, François Lemonnier, et al.. (2019). Colonic mucosa-associated lymphoid tissue lymphoma: a case series. Leukemia & lymphoma. 61(3). 582–587. 10 indexed citations
14.
Bras, Fabien Le, Valérie Molinier‐Frenkel, Aziz Guellich, et al.. (2017). Sequential cyclophosphamide-bortezomib-dexamethasone unmasks the harmful cardiac effect of dexamethasone in primary light-chain cardiac amyloidosis. European Journal of Cancer. 76. 183–187. 15 indexed citations
15.
16.
Bras, Fabien Le, Charikleia Kelaïdi, Thierry Lamy, et al.. (2011). Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion—The GFM experience. Leukemia Research. 35(11). 1444–1448. 28 indexed citations
17.
Depierre, A, T. Le Chevalier, E. Quoix, et al.. (1997). 1 Phase II trial of navelbine (NVB), in small cell lung cancer (SCLC). Lung Cancer. 18. 3–3. 5 indexed citations
18.
Degryse, H, Paul M. Parizel, A. M. De Schepper, et al.. (1994). Randomised double blind trial of the safety and efficacy of two gadolinium complexes (Gd-DTPA and Gd-DOTA). Neuroradiology. 36(1). 27–30. 28 indexed citations
19.
Sichez, J. P., et al.. (1991). Extraaxial cavernous hemangioma with hemorrhage.. PubMed. 12(5). 988–90. 10 indexed citations
20.
Gaston, André, Jean‐Paul Nguyen, M Djindjian, et al.. (1985). Vertebral haemangioma: CT and arteriographic features in three cases.. PubMed. 12(1). 21–33. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zhengming Jin Breakdown of academic impact, for papers by Denise Pereira Breakdown of academic impact, for papers by M. Yadira Hurley Breakdown of academic impact, for papers by Clara Cesana Breakdown of academic impact, for papers by Amer Beitinjaneh Breakdown of academic impact, for papers by Stephen J. Forman Breakdown of academic impact, for papers by Meifeng Tu Breakdown of academic impact, for papers by Alexey Maschan Breakdown of academic impact, for papers by Hien Liu Breakdown of academic impact, for papers by Keiki Kawakami
Rankless by CCL
2026